SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
|
pages:
1
|
presentations:
1 to
24 of
24
|
THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS, CHILDREN, AND ADULTS
Jintanat Ananworanich
US Military HIV Research Program, Thai Red Cross, Bethesda, MD, USA
ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV
Carl H June
University of Pennsylvania, Philadelphia, PA, USA
WEDNESDAY PLENARY SESSION
(PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH
Shannon L Hader
US Centers for Disease Control and Prevention, Atlanta, GA, USA
WEDNESDAY PLENARY SESSION
ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)
Barney S. Graham
NIAID, National Institutes of Health, Bethesda, MD, USA
IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK
Demetre C Daskalakis
NYC Department of Health and Mental Hygiene, New York, NY, USA
HTLV-1: THE OTHER HUMAN RETROVIRUS
Charles RM Bangham
Imperial College London, London, United Kingdom
Harnessing Antibodies for HIV-1 Prevention and Treatment
John R. Mascola
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
Antiretroviral Therapy: Where Are We Now? Where Are We Going?
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Progress in Gene Therapy for HIV Cure
Paula M. Cannon
University of Southern California, Los Angeles, CA, United States
HIV in Transgender Populations: Charted and Uncharted Waters
Tonia C. Poteat
Johns Hopkins University, Baltimore, MD, United States
Tuberculosis: Why Do I Have to Take So Many Pills?
Eric J. Rubin
Harvard School of Public Health, Boston, MA, United States
The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
John T. Brooks
Centers for Disease Control and Prevention, Atlanta, GA, United States
PrEP for HIV Prevention: What We Know and What We Still Need to Know for Implementation
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, United States
Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells
Stephen H. Hughes
National Cancer Institute, Frederick, MD, United States
Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now, and Where Are We Going?
Diana M. Gibb
University College London, London, United Kingdom
Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses
Michael Gale
University of Washington, Center for Innate Immunity and Immune Disease, Seattle, WA, United States
Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action
Steven Grinspoon
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
The Price of Selling Sex: HIV Among Female Sex Workers—The Context and the Public Health Response
Frances M. Cowan
University College London, London, United Kingdom
HPV Vaccines: Progress To Date and Future Worldwide Directions
Douglas R. Lowy
National Cancer Institute, Bethesda, MD, United States
HIV in People Who Use Drugs
Adeeba Kamarulzaman
University of Malaya, Kuala Lumpur, Malaysia
B-Cell Responses To HIV Infection: Challenges and Opportunities
Susan L. Moir
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
NeuroHIV in 2014: Beyond Dementia
Serena S. Spudich
Yale University, New Haven, CT, United States
HIV-1 Infection and Type-1 Interferon
Michael H. Malim
King's College London, London, United Kingdom
PEPFAR/Global Fund at 10 years: Past, Present, and Future
Stefano M. Bertozzi
University of California Berkeley School of Public Health, Berkeley, CA, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
|
pages:
1
|
presentations:
1 to
24 of
24
|
